Effect of 4 weeks treatment with Acipimox on left ventricular function, work capacity, insulin sensitivity and substrate metabolism in patients with chronic heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-002321-74-DK

Enrollment

Registered

2007-07-09

Start date

2007-08-29

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic stable heart failure MedDRA version: 9.1 Level: LLT Classification code 10008908 Term: Chronic heart failure

Interventions

Trade Name: olbetam Product Name: acipimox Pharmaceutical Form: Capsule* INN or Proposed INN: ACIPIMOX CAS Number: 51037300 Concentration unit: mg milligram(s) Concentration type: equal Concentration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic heart failure Ischemic heart disease Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Age 85, Recent myocardial infarction (<6 weeks), renal failure, Insulintreated diabetes, Gastric Ulcer, pregnancy

Design outcomes

Primary

Measure	Time frame
Main Objective: To test the the potential and the metabolic consequences of acipimox-treatment in chronic heart failure and the effects on cardiac metabolism;Secondary Objective: ;Primary end point(s): myocardial glucose- protein- and free fatty acid-extraction Global Left ventricular function Forearm (muscular metabolism)	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026